Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo ...

Veteran oncology executive brings global development and regulatory expertise to support TCB's life sciences strategy HOUSTON, TX, UNITED STAT ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Tammy Selleck, Senior Product Specialist at Qualifacts, will lead the session. Ms. Selleck brings a unique perspective, ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.